Local Drug Delivery for Coronary Artery Disease
eBook - ePub

Local Drug Delivery for Coronary Artery Disease

Established and Emerging Applications

  1. 622 pages
  2. English
  3. ePUB (mobile friendly)
  4. Available on iOS & Android
eBook - ePub

Local Drug Delivery for Coronary Artery Disease

Established and Emerging Applications

About this book

Pioneers in the field, the editors have assembled an excellent team of contributors with extensive experience of threatened vessel closure and restenosis, acute thrombosis, hyperproliferative cellular response, stents and local drug delivery. Comprehensive and up-to-date, this reference provides fully up-to-date information on currently available methods of drug delivery, as well as illustrations of drug delivery methods with seventy-five color and seventy-five black and white photos throughout the book. With this impressive presentation of the most up-to-date methods and applications, as well as a range of photographs illustrating their implementation, this guide is an excellent resource for cardiologists, pharmacologists, cardiac surgeons, and trainees.

Frequently asked questions

Yes, you can cancel anytime from the Subscription tab in your account settings on the Perlego website. Your subscription will stay active until the end of your current billing period. Learn how to cancel your subscription.
At the moment all of our mobile-responsive ePub books are available to download via the app. Most of our PDFs are also available to download and we're working on making the final remaining ones downloadable now. Learn more here.
Perlego offers two plans: Essential and Complete
  • Essential is ideal for learners and professionals who enjoy exploring a wide range of subjects. Access the Essential Library with 800,000+ trusted titles and best-sellers across business, personal growth, and the humanities. Includes unlimited reading time and Standard Read Aloud voice.
  • Complete: Perfect for advanced learners and researchers needing full, unrestricted access. Unlock 1.4M+ books across hundreds of subjects, including academic and specialized titles. The Complete Plan also includes advanced features like Premium Read Aloud and Research Assistant.
Both plans are available with monthly, semester, or annual billing cycles.
We are an online textbook subscription service, where you can get access to an entire online library for less than the price of a single book per month. With over 1 million books across 1000+ topics, we’ve got you covered! Learn more here.
Look out for the read-aloud symbol on your next book to see if you can listen to it. The read-aloud tool reads text aloud for you, highlighting the text as it is being read. You can pause it, speed it up and slow it down. Learn more here.
Yes! You can use the Perlego app on both iOS or Android devices to read anytime, anywhere — even offline. Perfect for commutes or when you’re on the go.
Please note we cannot support devices running on iOS 13 and Android 7 or earlier. Learn more about using the app.
Yes, you can access Local Drug Delivery for Coronary Artery Disease by Edoardo Camenzind,Ivan De Scheerder, Edoardo Camenzind, Ivan De Scheerder in PDF and/or ePUB format, as well as other popular books in Medicine & Cardiology. We have over one million books available in our catalogue for you to explore.

Information

Publisher
CRC Press
Year
2005
Print ISBN
9781841840451, 9781841840451
eBook ISBN
9781135417987
Topic
Medicine
Subtopic
Cardiology

Table of contents

  1. Cover
  2. Title Page
  3. Copyright Page
  4. Table of Contents
  5. List of contributors
  6. Preface
  7. 1 The purpose of site-specific therapy
  8. 2 Local drug delivery: impact of pressure,substance characteristics, and stenting on drug transfer into the arterial wall
  9. 3 Catheter-based and stent-based treatment for coronary artery disease
  10. 4 The ClearWay™ microporous balloon catheter
  11. 5 The DispatchÂŽ coronary infusion catheter
  12. 6 The Remedy™ PTCA dilatation infusion catheter
  13. 7 The Infiltrator™ angioplasty balloon catheter
  14. 8 The Infiltrator™ local drug delivery catheter
  15. 9 The needle catheter
  16. 10 Stent-mediated local drug delivery
  17. 11 Silicon carbide-coated stents
  18. 12 The Carbostent: a Carbofilm™-coated stent
  19. 13 The PC-coated BiodivYsio™ stent
  20. 14 PTFE-covered stents
  21. 15 Overview of drug delivery coatings
  22. 16 Phosphorylcholine (PC Technology™) coated stents as a drug delivery platform
  23. 17 Direct stent coating: an alternative for polymers?
  24. 18 Radioactive stents
  25. 19 Overview of potential drugs to inhibit in-stent restenosis
  26. 20 Direct antithrombins
  27. 21 Tissue factor inhibitors
  28. 22 Nitric oxide-related interventions and restenosis
  29. 23 Vitamin E and its multiple properties: anti, pro, and non-oxidative activities
  30. 24 The dexamethasone eluting stent
  31. 25 Antiinflammatory approaches to restenosis
  32. 26 The role of matrix metalloproteinase inhibitors after arterial injury
  33. 27 Methotrexate: a potential drug for stent-mediated local drug delivery: antiinflammatory and antiproliferative characteristics
  34. 28 Actin-skeleton inhibitors: potential candidates for local drug delivery in the prevention of in-stent restenosis?
  35. 29 Local delivery of antisense oligomers to c-myc for the prevention of restenosis
  36. 30 Site-specific delivery of cytostatic agents
  37. 31 Catheter-based delivery of NOS gene
  38. 32 Carbon-coated stents: diamond-like stent coatings
  39. 33 Long-term biocompatibility evaluation of poly-bis-trifluorethoxyphosphazene (PTFEP): a novel biodegradable polymer stent coating in a porcine coronary stent model
  40. 34 Biocompatibility evaluation of biosoluble stent coatings in a porcine coronary stent model
  41. 35 Glycoprotein (GP) IIb/IIIa receptor antagonist eluting stents
  42. 36 Activated protein C eluting stents
  43. 37 Local methylprednisolone (MP) delivery using a BiodivYsio phosphorylcholine (PC)-coated drug delivery stent reduces inflammation and neointimal hyperplasia in a porcine coronary stent model
  44. 38 Methotrexate-loaded BOBSC-coated coronary stents reduce neointimal hyperplasia in a porcine coronary model
  45. 39 Rapamycin eluting stents
  46. 40 Preclinical evaluation of tacrolimus-coated coronary stents
  47. 41 Local delivery of paclitaxel as a stent coating
  48. 42 Addition of cytochalasin D to a biodegradable oil stent coating inhibits intimal hyperplasia in a porcine coronary model
  49. 43 Vascular endothelial growth factor (VEGF) eluting stents
  50. 44 An advanced antisense for local vascular delivery for prevention of restenosis
  51. 45 Stent-based gene delivery
  52. 46 Catheter-based local heparin delivery
  53. 47 Local delivery of low molecular weight heparins
  54. 48 Local delivery of steroids before coronary stent implantation
  55. 49 Clinical studies with the Carbostent
  56. 50 Gold-coated stents
  57. 51 Heparin-coated stent trials
  58. 52 The Blue Medical 50% TEMPO coronary stent: preclinical studies and the first clinical pilot trial
  59. 53Dexamethasone: mode of action, preclinical, and clinical studies Ivan De Scheerder, Xiaoshun Liu, Yanming Huang, and Eric Verbeken
  60. 54 17ß-Estradiol eluting stents: a potential therapy in the prevention of restenosis
  61. 55 Batimastat: mode of action, preclinical, and clinical studies
  62. 56 The FIM trial: sirolimus eluting stents
  63. 57 Tacrolimus eluting stents
  64. 58 Everolimus eluting stents
  65. 59The Quanam drug eluting stent and the
  66. 60 The Boston Scientific paclitaxel eluting stent: TAXUS I and II
  67. 61 Clinical results with non-polymer based taxol eluting stents. The European evaLUation of pacliTaxel Eluting Stent (ELUTES) trial
  68. 62 Intrapericardial drug delivery for the prevention of restenosis
  69. 63 Alternatives to drug eluting stents: safety and efficacy of systemic delivery of antiproliferative therapy to reduce in-stent neointimal hyperplasia
  70. 64Drug eluting stents: a critical perspective1
  71. Index